- Home
- FORA vs BCAB Comparison
FORA vs BCAB Comparison
Compare FORA & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORA | BCAB |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 71.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FORA | BCAB |
|---|---|---|
| Price | $2.14 | $0.81 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 35.5K | ★ 2.1M |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,106,911.00 | N/A |
| Revenue This Year | $47.82 | N/A |
| Revenue Next Year | $10.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.47 | N/A |
| 52 Week Low | $1.64 | $0.24 |
| 52 Week High | $4.03 | $1.62 |
Technical Indicators
Market Signals| Indicator | FORA | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 46.79 | 49.25 |
| Support Level | $2.11 | $0.79 |
| Resistance Level | $2.20 | $0.90 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 55.00 | 31.27 |
Price Performance
Historical ComparisonAbout FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.